Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QYM1
- Development stage
- Preclinical
- Lead developer
- Qymune
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
QYM1 is a novel, first-in-class bispecific T-cell engager (TCE) designed for CD19-targeted B-cell depletion [0152]. Developed by Qymune using its proprietary Q²TCE (Quiet T Cell Engager) platform, QYM1 targets CD19 on B cells and the constant region of the αβ T-cell receptor (αβTCR) on T cells [0152]. This unique design decouples targeted B-cell cytotoxicity from cytokine release, establishing a wide therapeutic window with zero detectable cytokine release (such as IFNγ, TNFα, IL-6, and IL-1β) [0152]. QYM1 is in development for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and myasthenia gravis (MG), as well as B-cell lymphoma.
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on QYM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QYM1.